China Shineway Pharmaceutical Group Limited
CSWYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,778,043 | $4,516,538 | $588,092 | $498,181 |
| % Growth | -16.4% | 668% | 18% | – |
| Cost of Goods Sold | $946,294 | $1,122,419 | $150,694 | $125,678 |
| Gross Profit | $2,831,749 | $3,394,119 | $437,398 | $372,503 |
| % Margin | 75% | 75.1% | 74.4% | 74.8% |
| R&D Expenses | $100,522 | $110,462 | $17,484 | $17,419 |
| G&A Expenses | $291,320 | $326,499 | $279,804 | $256,557 |
| SG&A Expenses | $1,888,625 | $2,308,122 | $2,098,456 | $1,756,239 |
| Sales & Mktg Exp. | $1,597,305 | $1,981,623 | $1,818,652 | $1,499,682 |
| Other Operating Expenses | $0 | $0 | $104,980 | $82,853 |
| Operating Expenses | $1,989,147 | $2,418,584 | $331,175 | $289,920 |
| Operating Income | $842,602 | $975,535 | $106,223 | $82,583 |
| % Margin | 22.3% | 21.6% | 18.1% | 16.6% |
| Other Income/Exp. Net | $303,119 | -$800,073 | $30,285 | $28,705 |
| Pre-Tax Income | $1,145,721 | $175,462 | $136,508 | $111,288 |
| Tax Expense | $305,669 | $38,303 | $28,916 | $25,257 |
| Net Income | $840,052 | $137,159 | $107,592 | $86,031 |
| % Margin | 22.2% | 3% | 18.3% | 17.3% |
| EPS | 1.11 | 0.18 | 0.14 | 0.11 |
| % Growth | 516.7% | 28.6% | 27.3% | – |
| EPS Diluted | 1.11 | 0.18 | 0.14 | 0.11 |
| Weighted Avg Shares Out | 755,400 | 755,400 | 755,400 | 755,141 |
| Weighted Avg Shares Out Dil | 755,400 | 755,400 | 755,400 | 755,141 |
| Supplemental Information | – | – | – | – |
| Interest Income | $176,718 | $95,207 | $13,759 | $14,692 |
| Interest Expense | $6,129 | $2,737 | $94 | $194 |
| Depreciation & Amortization | $68,735 | $8,521 | $8,736 | $9,838 |
| EBITDA | $1,220,585 | $1,251,511 | $145,338 | $121,320 |
| % Margin | 32.3% | 27.7% | 24.7% | 24.4% |